Skip to main content

Design Therapeutics, Inc.

corporate_fare Company Profile

Design Therapeutics, Inc.

DSGN·NASDAQ·Life Sciences·CIK 0001807120

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the research and development of GeneTAC® molecules. These are a new class of small-molecule gene targeted chimera therapeutic candidates. The company designs these molecules to modify diseases by addressing the root cause of conditions resulting from inherited nucleotide repeat expansion mutations. Some diseases, like Friedreich ataxia (FA) and fragile X syndrome, involve reduced gene expression and a lack of vital proteins. Other diseases, such as myotonic dystrophy type-1 (DM1), Fuchs endothelial corneal dystrophy (FECD), and Huntington's disease (HD), are caused by nucleotide repeat expansions that produce toxic gene products, often linked to pathological nuclear foci, broad splicing disruptions, or mutant protein aggregates. Design Therapeutics' GeneTAC® small molecules are engineered to specifically target expanded genetic repeat sequences. They modulate gene expression by either increasing or decreasing mRNA transcription, depending on the disease's cause, with the goal of restoring cellular health. The company believes GeneTAC® molecules have broad potential for various unaddressed degenerative, monogenic nucleotide repeat expansion diseases globally. In preclinical studies for their lead FA program, the company observed restoration of frataxin (FXN) levels in multiple cell types from FA patients and in an in vivo murine model of FA using their FA GeneTAC® molecules. At well-tolerated doses in rodents and non-human primates (NHPs), FA GeneTAC® molecules reached the brain and heart, key organs affected by FA, at concentrations exceeding those needed to restore FXN levels in FA patient cells. Consistent with this biodistribution, increased endogenous FXN expression was observed in the brain and heart in an animal model of FA after treatment with FA GeneTAC® molecules.

Design Therapeutics, Inc. (NASDAQ:DSGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for DSGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for DSGN spans 10-Q, 8-K, 10-K.

Recent high-impact activity:

  • Design Therapeutics 10-Q: Q3 Loss $20.3M, $208.6M Cash, ATM Upsized to $200M
  • Design Therapeutics Reports Q2 2026 Results, RESTORE-FA Modifications, and Pipeline Progress
  • Design Therapeutics Modifies RESTORE-FA Trial, Initiates DT-818 Dosing, Reports Q2 Cash of $207.4M
  • Design Therapeutics Reports Positive Phase 1/2 DT-216P2 Data in Friedreich Ataxia, Plans Registrational Path
  • DT-216P2 Trial Shows Significant Clinical Improvements in Friedreich Ataxia; Design Therapeutics Plans Registrational Development

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$69.79M
Diluted EPS
-$1.22
Op. Cash Flow
-$54.36M
Free Cash Flow
-$54.55M
Operating Income
-$79.47M
Cash & Equivalents
$16.86M
Debt / Equity
0.00×
Shares Outstanding
60.4M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-098491

Short Interest & Short Volume

16.22 days to cover

FINRA reported short interest of 6,311,677 shares in DSGN as of the October 30, 2026 settlement, a 5.1% decrease from the prior period — about 16.2 days to cover at its recent average daily volume. On November 20, 2026, 72.7% of DSGN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,311,677 shares as of October 30, 2026
Change vs prior period▼ 5.1%
Days to cover16.22 at avg daily volume of 389,184
Daily short volume (FINRA facilities)72.7% of 67,004 shares on November 20, 2026
5-day average short volume71.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for DSGN, detected from its recent SEC filings · based on capital-structure filings through 2026-11-04.

1 recent capital raise1 shelf registration

New $300M Universal Shelf Filed · Stacks on $200M ATM Upsizing

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with D →
$9.02
52-week range · as of 2026-11-04 $6.16 – $17.25
Market cap
$577.61M
Volume
281.9K (0.7× avg)
3-mo avg 405.3K
Live data · 2026-11-22 03:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed DSGN - Latest Insights

DSGN
Nov 04, 2026, 4:11 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $10.63
Real-time Price: $9.02 info
Change: -$1.61 (-15%) info
Market Cap: $577.607M info
DSGN
Aug 03, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.12
Real-time Price: $9.02 info
Change: -$3.10 (-26%) info
Market Cap: $577.607M info
DSGN
Aug 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $12.12
Real-time Price: $9.02 info
Change: -$3.10 (-26%) info
Market Cap: $577.607M info
DSGN
May 18, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $18.33
Real-time Price: $9.02 info
Change: -$9.31 (-51%) info
Market Cap: $577.607M info
DSGN
May 18, 2026, 7:04 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $17.00
Real-time Price: $9.02 info
Change: -$7.98 (-47%) info
Market Cap: $577.607M info
DSGN
Apr 28, 2026, 4:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.81
Real-time Price: $9.02 info
Change: -$3.79 (-30%) info
Market Cap: $577.607M info
DSGN
Apr 28, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $12.81
Real-time Price: $9.02 info
Change: -$3.79 (-30%) info
Market Cap: $577.607M info
DSGN
Mar 09, 2026, 4:08 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $10.43
Real-time Price: $9.02 info
Change: -$1.41 (-14%) info
Market Cap: $577.607M info
DSGN
Mar 09, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.43
Real-time Price: $9.02 info
Change: -$1.41 (-14%) info
Market Cap: $577.607M info
DSGN
Mar 09, 2026, 4:01 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $10.43
Real-time Price: $9.02 info
Change: -$1.41 (-14%) info
Market Cap: $577.607M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets